[go: up one dir, main page]

MX2018012739A - Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva. - Google Patents

Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.

Info

Publication number
MX2018012739A
MX2018012739A MX2018012739A MX2018012739A MX2018012739A MX 2018012739 A MX2018012739 A MX 2018012739A MX 2018012739 A MX2018012739 A MX 2018012739A MX 2018012739 A MX2018012739 A MX 2018012739A MX 2018012739 A MX2018012739 A MX 2018012739A
Authority
MX
Mexico
Prior art keywords
cognitive function
leucine
acetyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2018012739A
Other languages
English (en)
Other versions
MX388461B (es
Inventor
Factor Mallory
Strupp Michael
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MX2018012739A publication Critical patent/MX2018012739A/es
Publication of MX388461B publication Critical patent/MX388461B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción está dirigida a acetilleucina o una sal farmacéuticamente aceptable de la misma para usarse en la mejora de la función cognitiva, movilidad o función cognitiva y movilidad en un sujeto, por ejemplo, en un sujeto anciano.
MX2018012739A 2016-04-19 2017-04-19 Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva. MX388461B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Publications (2)

Publication Number Publication Date
MX2018012739A true MX2018012739A (es) 2019-06-17
MX388461B MX388461B (es) 2025-03-20

Family

ID=58633040

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012739A MX388461B (es) 2016-04-19 2017-04-19 Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva.
MX2021014844A MX2021014844A (es) 2016-04-19 2018-10-18 Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014844A MX2021014844A (es) 2016-04-19 2018-10-18 Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.

Country Status (27)

Country Link
US (4) US10905670B2 (es)
EP (2) EP4501406A3 (es)
JP (3) JP7387264B2 (es)
KR (4) KR102632670B1 (es)
CN (2) CN118593463A (es)
AU (2) AU2017252507B2 (es)
BR (1) BR112018071547A2 (es)
CA (1) CA3021155A1 (es)
DK (1) DK3445351T3 (es)
ES (1) ES2994242T3 (es)
FI (1) FI3445351T3 (es)
HR (1) HRP20241552T1 (es)
HU (1) HUE069219T2 (es)
IL (3) IL262379B (es)
LT (1) LT3445351T (es)
MD (1) MD3445351T2 (es)
MX (2) MX388461B (es)
NZ (1) NZ747307A (es)
PL (1) PL3445351T3 (es)
PT (1) PT3445351T (es)
RS (1) RS66142B1 (es)
RU (1) RU2745912C2 (es)
SG (2) SG10202106190RA (es)
SI (1) SI3445351T1 (es)
SM (1) SMT202400459T1 (es)
WO (1) WO2017182802A1 (es)
ZA (1) ZA201806849B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4501406A3 (en) * 2016-04-19 2025-03-26 IntraBio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
LT3416631T (lt) 2016-08-11 2019-08-26 Intrabio Ltd Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN113348018B (zh) 2018-12-06 2025-04-01 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
IL321899A (en) * 2019-03-02 2025-09-01 Intrabio Ltd Leucine, acetyl leucine and related analogs for the treatment of disease
WO2025019570A1 (en) * 2023-07-18 2025-01-23 Sytheon Ltd. Novel amino acid based salts, compositions and methods for treating skin and rejuvenating skin and extending longevity
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
CA2687107A1 (en) * 2007-05-08 2008-11-13 Northern Innovations And Formulations Corp. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
US20120196257A1 (en) * 2009-08-27 2012-08-02 Joe Verghese Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
EP4501406A3 (en) * 2016-04-19 2025-03-26 IntraBio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
US12458614B2 (en) * 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders

Also Published As

Publication number Publication date
KR20220038814A (ko) 2022-03-29
EP3445351A1 (en) 2019-02-27
JP2022024058A (ja) 2022-02-08
AU2017252507A1 (en) 2018-11-08
EP3445351B1 (en) 2024-10-16
CA3021155A1 (en) 2017-10-26
LT3445351T (lt) 2024-11-25
ES2994242T3 (en) 2025-02-05
IL293266B2 (en) 2024-07-01
US10905670B2 (en) 2021-02-02
HUE069219T2 (hu) 2025-02-28
JP2024123087A (ja) 2024-09-10
KR20240018683A (ko) 2024-02-13
RS66142B1 (sr) 2024-12-31
KR102791288B1 (ko) 2025-04-03
US12329733B2 (en) 2025-06-17
CN118593463A (zh) 2024-09-06
RU2021107001A (ru) 2021-04-12
CN109069463A (zh) 2018-12-21
KR102413754B1 (ko) 2022-06-27
NZ747307A (en) 2025-10-31
IL262379B (en) 2022-07-01
JP7387264B2 (ja) 2023-11-28
WO2017182802A1 (en) 2017-10-26
MX2021014844A (es) 2022-01-18
IL293266B1 (en) 2024-03-01
US20190083438A1 (en) 2019-03-21
KR102632670B1 (ko) 2024-02-01
JP7506046B2 (ja) 2024-06-25
PL3445351T3 (pl) 2025-01-07
US11998518B2 (en) 2024-06-04
RU2018140131A3 (es) 2020-05-14
SG10202106190RA (en) 2021-07-29
SMT202400459T1 (it) 2025-01-14
AU2022256077A1 (en) 2022-11-17
DK3445351T3 (da) 2024-11-04
KR20180134398A (ko) 2018-12-18
CN109069463B (zh) 2024-07-23
IL310508A (en) 2024-03-01
FI3445351T3 (fi) 2024-11-18
EP4501406A2 (en) 2025-02-05
HRP20241552T1 (hr) 2025-01-17
JP2019513814A (ja) 2019-05-30
US20250332133A1 (en) 2025-10-30
KR20220093386A (ko) 2022-07-05
IL262379A (en) 2018-11-29
EP4501406A3 (en) 2025-03-26
RU2745912C2 (ru) 2021-04-02
MD3445351T2 (ro) 2024-12-31
US20210106548A1 (en) 2021-04-15
PT3445351T (pt) 2024-11-14
US20230346732A1 (en) 2023-11-02
ZA201806849B (en) 2019-07-31
SG11201809031XA (en) 2018-11-29
RU2018140131A (ru) 2020-05-14
IL293266A (en) 2022-07-01
MX388461B (es) 2025-03-20
AU2017252507B2 (en) 2022-07-21
BR112018071547A2 (pt) 2019-03-06
SI3445351T1 (sl) 2025-04-30

Similar Documents

Publication Publication Date Title
MX2018012739A (es) Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.
IL269642A (en) Methods and compositions for enhancing health
CL2017003033A1 (es) Dispositivo de monitorización para la aplicación de un fármaco con una pluma de fármaco, con registro, comunicación y alarmas.
MX2018011216A (es) Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
TWD172100S (zh) 化粧瓶
TWD178500S (zh) 護膚器
TWD169675S (zh) 掛鉤
IL280809B (en) Novel compositions, their use, and methods for their formation
EP3414224A4 (en) INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)
TWD187490S (zh) 病患連接裝置
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
TWD166031S (zh) 口含物
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX385447B (es) Agente antihipertensivo
IL268092B (en) Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
HUE055298T2 (hu) Készítmények speciális tenzidekkel és nagy mennyiségekben glicerinnel
TWD180565S (zh) 塗抹器
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
TWD195659S (zh) Washstand
TWD176882S (zh) 按摩裝置
TWD196366S (zh) 包裝用容器
TWD170668S (zh) 記事板
TWD184785S (zh) 化妝品施用器
TWD179590S (zh) 化妝品容器